Leaner Genmab A More Likely Buy For GSK?
This article was originally published in The Pink Sheet Daily
Executive Summary
Staff cutbacks, dropped programs, and out-licensing plans unveiled.
You may also be interested in...
Survey: Oncologists Show Support For Erbitux Uptake Based On KRAS Test
Approach could encourage front-line Erbitux use in some colorectal patients, Rodman & Renshaw finds after oncologist survey.
Genmab, GSK On Track To File Ofatumumab For CLL In Late 2008
Positive top-line Phase III results show response rates as high as 51 percent.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf